Home » nephropathy
Tag:

nephropathy

Health

IBD Meds & Kidney Disease: Caution & Risks

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

IBD and Kidney Disease: Navigating Treatment Options and Future Risks

Up to 23% of individuals battling inflammatory bowel disease (IBD) also grapple with chronic kidney disease (CKD), a combination that significantly complicates treatment decisions. While newer therapies, particularly biologic agents, generally appear safe for those with compromised kidney function, a recent review underscores the critical need for caution with conventional drugs and emerging treatments like JAK inhibitors. This isn’t simply about adjusting dosages; it’s about safeguarding kidney health while effectively managing a debilitating digestive condition.

The Complex Interplay of IBD and Kidney Health

The link between IBD and CKD isn’t fully understood, but several factors are believed to contribute. Chronic inflammation, a hallmark of IBD, can directly damage the kidneys. Furthermore, the medications used to treat IBD can themselves impact renal function, as the kidneys are responsible for processing and eliminating these drugs. This is especially true in advanced CKD, where the kidneys’ ability to filter is significantly reduced. A recent study, led by Lynna Chen at Monash University, meticulously reviewed existing research to provide clearer guidance for physicians facing this challenge.

Conventional Therapies: Where Caution is Key

The review highlights specific concerns with several commonly used IBD treatments. Mesalazine, an aminosalicylate, carries a risk of triggering acute interstitial nephritis – inflammation within the kidneys. Even low doses of methotrexate, an immunomodulator, can lead to irreversible kidney damage, bone marrow suppression, and increased mortality in patients on dialysis. Calcineurin inhibitors, another class of immunomodulators, are known to be nephrotoxic, reducing blood flow to the kidneys and hindering their filtering capacity. These findings emphasize the importance of careful patient selection and vigilant monitoring when utilizing these medications in individuals with CKD.

Biologics Offer a Safer Profile, But Vigilance Remains

Fortunately, the news isn’t all concerning. The study found that monoclonal antibodies – including anti-TNF, anti-integrin, and anti-interleukin therapies – demonstrated a relatively safe profile even in patients with renal insufficiency and those undergoing hemodialysis. These biologic agents target specific components of the immune system, offering effective IBD control with a lower risk of direct kidney damage. However, researchers stress that ongoing monitoring of kidney function is still crucial, even with these therapies.

JAK Inhibitors and Thiopurines: Dosage Adjustments are Essential

The landscape becomes more nuanced with newer treatments. JAK inhibitors, a class of small molecule drugs, and thiopurines require dose adjustments in advanced renal disease to prevent drug accumulation and potential toxicity. Conversely, S1P receptor modulators appear to be safe for use in CKD without dosage modifications. This variability underscores the need for a highly individualized approach to treatment, tailored to the patient’s specific kidney function and the drug’s pharmacokinetic properties.

The Future of IBD Treatment in CKD: Personalized Medicine and Predictive Modeling

Looking ahead, the management of IBD in patients with CKD is poised for significant advancements. The current emphasis on “one-size-fits-all” dosing is likely to give way to more personalized approaches. Pharmacogenomics – the study of how genes affect a person’s response to drugs – will play an increasingly important role in predicting which patients are most likely to benefit from specific therapies and which are at higher risk of adverse effects. Furthermore, the development of predictive models, incorporating factors like kidney function, disease severity, and genetic predisposition, could help clinicians proactively adjust treatment plans to minimize renal compromise.

The rise of biosimilars – more affordable versions of biologic drugs – also presents both opportunities and challenges. While biosimilars can improve access to essential therapies, careful monitoring will be needed to ensure their safety and efficacy in patients with CKD. Research is also needed to explore novel therapeutic targets and develop drugs specifically designed to minimize renal toxicity.

Ultimately, effectively managing IBD in the presence of CKD requires a collaborative effort between gastroenterologists, nephrologists, and pharmacists. Diligent surveillance of renal function, coupled with a tailored treatment strategy, is paramount to optimizing patient outcomes and preserving kidney health. What are your predictions for the role of artificial intelligence in personalizing IBD treatment for patients with co-existing kidney disease? Share your thoughts in the comments below!

National Kidney Foundation – IBD and Kidney Disease

0 comments
0 FacebookTwitterPinterestEmail
Health

Pegcetacoplan: Sustained Kidney Benefit at 52 Weeks

by Alexandra Hartman Editor-in-Chief
written by Alexandra Hartman Editor-in-Chief

Pegcetacoplan Shows Sustained Kidney Benefits in C3 Glomerulopathy, IC-MPGN Patients

Table of Contents

Data unveiled at the 62nd European Renal Association (ERA) Congress 2025 demonstrates that pegcetacoplan, a targeted C3/C3b inhibitor, continues to show significant positive effects on key indicators of kidney disease in individuals suffering from C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

The findings, stemming from the 52-week results of the VALIANT trial, indicate that patients experienced robust and sustained improvements. Fadi Fakhouri, M.D., from Lausanne University Hospital, presented the compelling data, highlighting the drug’s potential to transform treatment approaches for these rare kidney conditions.

Sustained Reduction in Proteinuria

The initial 26-week results of the VALIANT trial, which were presented at Kidney Week 2024, showcased a significant difference in proteinuria reduction.Proteinuria is measured by the urine protein-to-creatinine ratio (uPCR).

The pegcetacoplan group saw a 67.2% reduction compared to a mere 2.9% with placebo (P < .0001). The latest 52-week data revealed that these benefits were not only sustained in patients who remained on pegcetacoplan, but also mirrored in those who switched from placebo to the active treatment.

Key Findings From The Valiant Trial

  • Patients initially on pegcetacoplan maintained a significant proteinuria reduction, with uPCR changes of -67.2% at week 26 and -68.3% at week 52.
  • Patients who switched from placebo to pegcetacoplan experienced a -51.3% reduction in uPCR at week 52.
  • E GFR levels remained relatively stable in both groups, indicating preservation of kidney function.

For context, recent studies have shown a direct correlation between proteinuria reduction and improved long-term kidney outcomes, emphasizing the clinical importance of these results.

Impact on Kidney Function (E GFR)

Estimated Glomerular Filtration Rate (eGFR) levels, a critical measure of kidney function, showed slight changes. The pegcetacoplan group experienced a minor decrease from -1.2 mL/min/1.73 m2 at week 26 to -3.7 mL/min/1.73 m2 at week 52.

Comparatively, the placebo-to-pegcetacoplan group saw changes of -7.9 mL/min/1.73 m2 at week 26 and -4.7 mL/min/1.73 m2 at week 52. Pro Tip: Monitoring eGFR regularly is crucial for managing kidney disease progression.

Safety And Tolerability

Pegcetacoplan continued to demonstrate a favorable safety profile throughout the second 26 weeks of the trial.Treatment-emergent adverse events (TEAEs) were similar between the two groups during the open-label period: 77% in the pegcetacoplan-to-pegcetacoplan group and 73.7% in the placebo-to-pegcetacoplan group.

Notably, infusion-related TEAEs decreased from the randomized to open-label period in the pegcetacoplan-to-pegcetacoplan group (33.3% vs 9.8%, respectively), suggesting improved tolerability over time. Adherence to the treatment was remarkably high, with 97.6% of patients showing adherence rates between 90% and 100%.

Subgroup Analyses: Nephrotic Range Proteinuria and Immunosuppressive Therapies

Further analyses focused on patients with nephrotic range proteinuria at baseline, a population at high risk of rapid disease progression. Among these patients, those treated with pegcetacoplan experienced a relative reduction in proteinuria of 72.1% compared to placebo (P <.0001) after the initial 26-week period.

Another subanalysis assessed outcomes among patients receiving concomitant immunosuppressive therapy at baseline. The results were consistent, with immunosuppressant-treated patients receiving pegcetacoplan showing a relative reduction of 70% in proteinuria compared to placebo (P = .0005).

David Kavanagh, M.D., emphasized the meaning, noting that a ≥50% reduction in proteinuria can substantially reduce the risk of kidney failure.

Comparative Overview of Pegcetacoplan Trial Results

outcome Pegcetacoplan Group (Week 52) Placebo-to-pegcetacoplan Group (Week 52)
uPCR Change -68.3% -51.3%
E GFR Change -3.7 mL/min/1.73 m2 -4.7 mL/min/1.73 m2
Adherence Rate 97.6% (≥90% adherence) 97.6% (≥90% adherence)

These results collectively underscore the potential of pegcetacoplan as a significant therapeutic option for patients with C3 glomerulopathy and IC-MPGN, particularly those at high risk of disease progression.

The Broader Impact of Complement Inhibition in Kidney Disease

Pegcetacoplan’s success highlights the growing importance of complement inhibition as a therapeutic strategy in kidney diseases.the complement system, a part of the immune system, can become overactive in certain kidney disorders, leading to inflammation and damage.

Targeting specific components of this system, like C3, offers a precise way to reduce kidney injury. Ongoing research continues to explore novel complement inhibitors and their potential to improve outcomes in various kidney diseases. Did You Know? Complement-targeted therapies are also being investigated for other autoimmune conditions beyond kidney disease.

Future Directions in C3 Glomerulopathy and IC-MPGN Treatment

While pegcetacoplan represents an advancement, the treatment landscape for C3 glomerulopathy and IC-MPGN is still evolving. Future research will likely focus on:

  • Identifying biomarkers to predict treatment response.
  • Developing personalized treatment approaches based on individual disease characteristics.
  • Exploring combination therapies to maximize kidney protection.

Frequently Asked Questions About Pegcetacoplan and Kidney disease

What is Pegcetacoplan, And How Does It Work?

pegcetacoplan is a targeted C3/C3b inhibitor used to treat C3 glomerulopathy and IC-MPGN. It works by blocking the complement system, reducing inflammation and kidney damage.

What Are The Primary Benefits Of Pegcetacoplan Observed In The Valiant Trial?

The VALIANT trial showed that pegcetacoplan leads to sustained reductions in proteinuria and stabilization of kidney function (eGFR) in patients with C3 glomerulopathy and IC-MPGN.

Is Pegcetacoplan Safe For Long-Term Use?

In the VALIANT trial, pegcetacoplan was generally well-tolerated over 52 weeks, with a favorable safety profile and high adherence rates.

Can Pegcetacoplan Be Used In Patients Already On immunosuppressants?

Yes, subanalysis from the VALIANT trial showed that patients on concomitant immunosuppressive therapy also experienced significant benefits from pegcetacoplan.

What Is Proteinuria, And Why Is Reducing It Critically important In Kidney Disease?

Proteinuria is the presence of excess protein in the urine, indicating kidney damage. Reducing proteinuria is crucial because it can slow the progression of kidney disease and reduce the risk of kidney failure.

Do these findings offer hope for better kidney disease management? What are your thoughts on targeted therapies like pegcetacoplan? Share your insights and questions below.

Given the 52-week data, what are the most significant long-term implications of pegcetacoplan treatment for patients with complement-mediated kidney diseases?

Pegcetacoplan and Sustained Kidney Benefit at 52 Weeks: A Deep Dive

Pegcetacoplan, known by its brand name Empaveli, has emerged as a significant treatment option for several kidney conditions. This article provides a extensive overview of the kidney benefits of pegcetacoplan, particularly at the 52-week mark. We’ll explore its mechanism of action, clinical trial results, and the implications for patients navigating kidney disease treatment.

Understanding Pegcetacoplan’s Mechanism and Target Diseases

Pegcetacoplan is a complement C3 inhibitor.It functions by specifically targeting the complement system, a critical part of the immune system involved in inflammation and cellular damage. in specific kidney conditions, an overactive complement system can contribute to disease progression. By inhibiting C3,pegcetacoplan aims to reduce this harmful inflammatory response,thereby mitigating kidney damage. This mechanism of action is central to its effectiveness in various complement-mediated kidney diseases.

Pegcetacoplan is currently approved for the treatment of certain conditions, including, but not limited to:

  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • C3 glomerulopathy (C3G): a rare kidney disease.
  • Atypical Hemolytic Uremic Syndrome (aHUS) particularly where complement dysregulation is the cause.

Clinical trial Results: 52-Week data Analysis

The primary objective of many clinical trials evaluating pegcetacoplan is to determine the long-term safety and efficacy, specifically focusing on kidney function at 52 weeks. these trials aim to demonstrate long-term kidney health enhancement. Studies consistently analyse patients’ overall health and how their kidney function has changed during the course of treatment. The 52-week outcomes are crucial in establishing pegcetacoplan’s role in chronic kidney disease (CKD) management.

Parameter Typical Outcomes (Examples from Trials) Meaning
eGFR Change Stabilization or Improvement (compared to decline in untreated control) Indicates slowing progression of kidney damage and improved kidney function.
Proteinuria Reduction Significant decrease in urinary protein levels (e.g., reduction in urine protein-to-creatinine ratio [UPCR]). Suggests reduced glomerular damage and improvement in kidney filtration.
Reduction in C3 levels Marked decrease in serum C3 levels, indicative of complement system inhibition. Confirms the drug’s intended mechanism of action and effectiveness.

Several clinical trials have reported positive results at 52 weeks. These trials frequently monitor eGFR (estimated Glomerular Filtration Rate), which serves as an indicator of kidney function. Furthermore, there is an in-depth observation of the patient’s response levels to pegcetacoplan therapy.

Patient Viewpoint: real-World Implications of Pegcetacoplan

The implementation of pegcetacoplan represents a shift in the landscape of kidney disease treatment. Patients receiving this therapy often experience significant improvements in their quality of life.The potential benefits of pegcetacoplan include reduced dialysis dependency, decreased frequency of hospitalizations, and perhaps prolonged kidney survival. Here’s how the 52-week data translates to patient experiences:

  • Improved Well-being: By slowing the progression of kidney damage, pegcetacoplan can lead to fewer debilitating symptoms and a general improvement in the patient’s daily life.
  • Reduced Risk of Complications: Controlling the complement system may reduce the risk of kidney problems, reducing the likelihood of life-threatening interventions.
  • Enhanced Treatment Options: pegcetacoplan provides an alternative treatment strategy for patients who might have limited options earlier.

Practical Tips and Considerations for Patients

Patients, in particular, should follow their physicians’ guidance. Managing kidney health with pegcetacoplan necessitates a collaborative approach between the treatment provider and the patient. It is essential to work closely with your healthcare provider to understand your individual response to therapy. Here are some practical tips:

  • Regular Monitoring: Schedule regular checkups to supervise kidney function and assess side effects.
  • Adherence to Treatment: Ensuring pegcetacoplan infusions are managed correctly. Adherence to treatment schedules is essential for maintaining the drug’s effectiveness.
  • Lifestyle Management: Implement lifestyle changes such as a balanced diet and sufficient hydration to take care of the kidney health.
  • Patient Support: Leverage patient support groups and educational resources to learn more about the condition and kidney disease treatment.

Safety and Side Effects of Pegcetacoplan

While pegcetacoplan shows promising results, it’s essential to address the drug’s safety profile. As is the case with most medications, there are potential side effects of pegcetacoplan that patients should be aware of. The most commonly reported side effects include:

  • Injection site reactions, such as pain, redness, and swelling.
  • Risk of serious infections, particularly encapsulated bacterial infections.
  • Anemia
  • Headaches.

patients should discuss potential side effects with their healthcare providers.The benefits of pegcetacoplan must be carefully measured against the potential side effects, with continuous monitoring for any adverse reactions being essential.

Conclusion: Pegcetacoplan’s Role in Kidney Disease Management

Pegcetacoplan has the potential to transform chronic kidney disease treatment. The positive 52-week data support the notion that it can offer remarkable benefits for kidney health. As the medical community accumulates more evidence from clinical trials and real-world experiences, pegcetacoplan’s long-term safety and efficiency will continue to be verified. Patients and healthcare professionals should consider pegcetacoplan as another significant step to protecting kidney health and improving patient outcomes.

0 comments
0 FacebookTwitterPinterestEmail
Health

IgAN Treatment: Nefecon Works at Any Kidney Function Level

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

IgAN Treatment Breakthrough: Nefecon Shows Promise Across All Kidney Function Levels

For the millions worldwide battling immunoglobulin A nephropathy (IgAN), a progressive kidney disease, a new analysis offers a significant ray of hope. Data presented at the European Renal Association (ERA) Congress 2025 reveals that Nefecon, an oral budesonide formulation, demonstrably slowed kidney function decline in patients regardless of their initial kidney health – a finding that could reshape treatment strategies and improve outcomes for a broader patient population.

Understanding the Challenge of IgAN and eGFR

IgAN is characterized by deposits of immunoglobulin A in the kidneys, leading to inflammation and, eventually, reduced kidney function. A key metric for assessing kidney health is the estimated glomerular filtration rate (eGFR), which measures how well the kidneys filter waste from the blood. Traditionally, treatment efficacy has been evaluated with an eye toward patients with varying eGFR levels, but a consistent benefit across the spectrum has been elusive. This new subanalysis of the pivotal NeflgArd study changes that narrative.

NeflgArd Subanalysis: Consistent Benefit Across the Board

The NeflgArd study randomly assigned patients with primary IgAN to receive either 16mg of Nefecon daily or a placebo, alongside standard supportive care including renin-angiotensin system inhibition. Researchers then stratified patients based on their baseline eGFR, creating deciles ranging from below 38 mL/min/1.73 m2 to above 82 mL/min/1.73 m2. The results were compelling: Nefecon demonstrated a benefit in preserving eGFR across nearly all these groups.

Greater Impact in Higher eGFR Groups

While benefits were observed across the board, the study highlighted a particularly pronounced effect in patients with higher baseline eGFR levels (above 72 mL/min/1.73 m2). This suggests that early intervention with Nefecon may be especially impactful in slowing disease progression before significant kidney damage occurs. Furthermore, reductions in urine protein-creatinine ratio – a marker of kidney damage – were consistently observed with Nefecon as early as month 9 and sustained through 24 months.

Targeted Drug Delivery: The Nefecon Advantage

Nefecon’s unique targeted-release formulation is central to its success. Unlike traditional budesonide, Nefecon is designed to release the drug specifically into the distal ileum, minimizing systemic absorption and maximizing its anti-inflammatory effect in the gut-kidney axis. This targeted approach is believed to reduce inflammation that contributes to IgAN progression. Research into the gut-kidney axis is rapidly expanding, highlighting the importance of this connection in kidney disease.

Implications for Future IgAN Treatment

The findings from the NeflgArd subanalysis have several important implications. First, they support a more universal approach to IgAN treatment with Nefecon, regardless of a patient’s initial kidney function. Second, they reinforce the potential of targeted drug delivery systems to improve efficacy and reduce side effects. Finally, they underscore the importance of early intervention in IgAN to maximize the benefits of treatment.

The Rise of Personalized Kidney Care

Looking ahead, we can anticipate a shift towards more personalized approaches to IgAN management. While Nefecon offers a significant advance, future research will likely focus on identifying biomarkers to predict individual patient responses and tailoring treatment strategies accordingly. The integration of genetic testing and advanced imaging techniques could further refine risk stratification and optimize therapeutic interventions. The concept of precision medicine in nephrology is gaining momentum, promising a future where treatments are tailored to the unique characteristics of each patient.

“We should be confident about treating people with Nefecon across the full range of eGFR,” stated Dr. Jonathan Barratt, lead author of the study. This confidence, backed by robust data, marks a turning point in the management of IgAN.

What are your thoughts on the potential of targeted therapies like Nefecon to revolutionize kidney disease treatment? Share your perspective in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Sparsentan Approved for Kidney Disease

by Alexandra Hartman Editor-in-Chief
written by Alexandra Hartman Editor-in-Chief

nice Recommends Sparsentan (filspari) For Iga Nephropathy Treatment: A Breakthrough for Patients

In A important reversal, the National Institute For Health And Care Excellence (Nice) has issued a positive recommendation for sparsentan (filspari) as a treatment for primary immunoglobulin A nephropathy (IgaN) in adults. this decision marks a pivotal moment for individuals affected by Iga nephropathy, offering a new therapeutic option where choices have been limited.

Nice Reverses Earlier Decision, Approves Funding For Sparsentan

Nice previously rejected NHS funding for sparsentan in February, citing concerns over its value for money. however,following the manufacturer’s provision of additional data and an agreed price discount,Nice has now endorsed the drug. This reversal brings new hope to thousands living with IgaN.

clinical Trials Demonstrate Significant Benefits Of sparsentan

Clinical evidence indicates that sparsentan is more effective in reducing urine protein-to-creatinine ratio (Upcr) compared to standard treatments. Nice noted that the drug also shows promise in maintaining kidney function more effectively. The final draft guidance recommends sparsentan for IgaN patients with a urine protein excretion of 1.0 g/day or higher, or a Upcr of 0.75 g/g or higher.

Treatment should be discontinued after 36 weeks if a patient’s Upcr remains at or above 1.76 g/g and has not decreased by at least 20%. This ensures that the medication is effective and beneficial for the patient.

Impact On patients With Iga Nephropathy

IgaN affects over 18,000 individuals in England and is a leading cause of chronic kidney disease and kidney failure. This new recommendation could positively impact over 4,200 people with chronic kidney disease. Standard care typically involves angiotensin-2 receptor blockers like irbesartan.

Did You Know? IgaN frequently enough affects younger individuals, perhaps impacting their family and career life. This approval can help maintain their quality of life.

How Does Sparsentan Work?

Sparsentan functions by blocking receptors for endothelin-1 and angiotensin Ii, two hormones that contribute to kidney damage. this blockage reduces proteinuria and slows the progression of kidney damage. Clinical trials have demonstrated that sparsentan reduces Upcr more effectively than irbesartan and suggests better maintenance of kidney function.

Key Findings From The Protect Study

The Protect study, a phase 3 trial, substantially influenced Nice’s recommendation.This double-blind, randomized study involved patients with biopsy-proven primary IgaN and proteinuria of at least 1.0 g daily, despite maximized renin-angiotensin system inhibition for at least 12 weeks.

Participants were randomly assigned to receive either 400 mg of oral sparsentan or 300 mg of oral irbesartan daily. The sparsentan group exhibited slower rates of estimated glomerular filtration rate (Egfr) decline. At 36 weeks, there was a ample reduction in proteinuria, which persisted throughout the study.

By 110 weeks, proteinuria, measured by changes in Upcr from baseline, was 40% lower in the sparsentan group compared to those on irbesartan. The composite kidney failure endpoint was reached by 9% of patients in the sparsentan group versus 13% in the irbesartan group.

Researchers concluded that sparsentan treatment resulted in significant reductions in proteinuria and preserved kidney function compared to maximally titrated irbesartan in IgaN patients.

Advantages Of Sparsentan Treatment

Sparsentan is administered as a once-daily tablet for long-term use, setting it apart from treatments like targeted-release budesonide, which is limited to a 9-month duration. Nice anticipates that this treatment will alleviate pressure on the NHS by preventing or delaying progression to end-stage renal disease requiring dialysis or transplant.

Helen Knight, director of medicines evaluation at Nice, highlighted the current limited treatment options for IgaN and emphasized the long-term benefits that sparsentan offers. Fiona Loud, policy director at Kidney Care Uk, also welcomed the guidance, noting the significant impact IgaN has on younger patients.

igan Treatment Options Comparison

Treatment Administration Duration Benefits
Sparsentan (Filspari) Once-daily tablet Long-term Reduces proteinuria, preserves kidney function
irbesartan Oral medication Ongoing Standard treatment, manages blood pressure
Budesonide Targeted-release 9 months Anti-inflammatory effects

Understanding iga nephropathy

Iga nephropathy, also known as Berger’s disease, is a kidney disease that occurs when immunoglobulin A (Iga) builds up in the kidneys, causing inflammation and damage. This can impair the kidneys’ ability to filter waste from the blood.

According to a recent study by the National Kidney Foundation, early diagnosis and management of IgaN are crucial in slowing disease progression and preventing kidney failure. Regular monitoring of kidney function and proteinuria levels can definitely help healthcare professionals tailor treatment plans effectively.

Pro Tip: Patients should maintain a healthy lifestyle, including a balanced diet and regular exercise, to support kidney health and overall well-being.

The Future Of Iga Nephropathy Treatment

the approval of sparsentan represents a significant advancement, but research continues. Scientists are exploring new therapies targeting different aspects of the disease, including treatments aimed at reducing Iga production and preventing its accumulation in the kidneys.

Ongoing clinical trials are evaluating the effectiveness of various novel agents, offering hope for even more effective treatments in the future. Staying informed about these developments can empower patients and healthcare providers to make the best decisions regarding IgaN management.

Frequently Asked Questions About Sparsentan and Iga Nephropathy

  • What Is Sparsentan And How Does It Treat Iga Nephropathy? Sparsentan (Filspari) is a medication that blocks receptors for endothelin-1 and angiotensin Ii,reducing proteinuria and slowing kidney damage in patients with Iga nephropathy.
  • What Were The Main Findings Of The Protect Study On Sparsentan? The Protect study showed that sparsentan significantly reduced proteinuria and preserved kidney function compared to irbesartan in patients with Iga nephropathy.
  • Who Is Eligible for Sparsentan Treatment According To Nice Guidelines? Nice recommends sparsentan for adults with Iga nephropathy who have a urine protein excretion of 1.0 g/day or higher, or a Upcr of 0.75 g/g or higher.
  • How Often Is Sparsentan Taken, And For How Long? Sparsentan is taken as a once-daily tablet for long-term use, unlike some other treatments with limited durations.
  • What Are The Benefits Of Sparsentan Compared To Standard Treatments For Iga nephropathy? Sparsentan has been shown to reduce urine protein levels more effectively and may better maintain kidney function compared to standard treatments like irbesartan.
  • How Does Sparsentan Help The Nhs? Nice expects that sparsentan will reduce pressure on the Nhs by preventing or delaying the progression of Iga nephropathy to end-stage renal disease, thus reducing the need for dialysis or transplant.

What are your thoughts on this new treatment option for Iga nephropathy? Share your comments below.

Disclaimer: this article provides general information and should not be considered medical advice.Consult with a healthcare professional for personalized guidance.

0 comments
0 FacebookTwitterPinterestEmail
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.